Chaput Laure, Pons-Rejraji Hanae, Chabrolles Hélène, Fiot Mélanie, Lucas Cécily, Pereira Bruno, Bonnet Benjamin, Haj Hamid Rahaf, Rives-Feraille Aurélie, Binois Olivier, Ferreux Lucile, Delepine Béatrice, Koscinski Isabelle, Lichtblau Isabelle, Giscard d'Estaing Sandrine, Bendayan Marion, Saias-Magnan Jacqueline, Lousqui Johanna, Henquell Cécile, Brugnon Florence
CHU Clermont-Ferrand, Service AMP-CECOS (Centre d'Etude et de Conservation des Œufs et du Sperme Humain), Clermont-Ferrand, France.
Université Clermont Auvergne, INSERM 1240, IMoST (Imagerie Moléculaire et Stratégies Théranostiques), Clermont-Ferrand, France.
J Med Virol. 2024 Dec;96(12):e70070. doi: 10.1002/jmv.70070.
The COVID-19 pandemic, driven by SARS-CoV-2, led authorities to recommend halting assisted reproductive technology programs, focusing instead on fertility preservation, for cancer patients. The presence of SARS-CoV-2 in semen remains controversial. This multicentric prospective cohort study, conducted across 12 university medical centers, aimed to determine if SARS-CoV-2 is present in spermatozoa/seminal plasma in cancer patients by RT-PCR and to assess its impact on standard semen parameters. The levels of cytokines and TNF-α were measured in seminal fluid by ELISA. We enrolled 129 men who underwent sperm cryopreservation between July 7, 2020, and June 30, 2021. The 63 were included and tested for COVID-19 in nasal swab samples by RT-PCR and/or by serology. All patients were asymptomatic on the day of semen collection: 50 were uninfected, 8 had a positive nasal swab (PCR+) and 5 were seropositive. SARS-CoV-2 RNA was not detected in the seminal fluid or spermatozoa. Ejaculate volume was significantly lower in the PCR+ group compared to the uninfected group (median [IQR]: 2.6 mL [1.6-3.4] vs. 4.6 mL [2.6-5.2] p < 0.05). Total and progressive motility were lower in the PCR+ group compared to the seropositive group (32.5% [25.0-45.0] vs. 50% [49.0-55.0] p < 0.05, and 22.5% [10.0; 32.5] vs. 44.5% [40-49] p < 0.05). Higher TNF-α level was observed in the PCR+ group (1.9 pg/mL [0-3.9]) compared to the uninfected group (0 pg/mL [0-0.4]) p < 0.05. Although SARS-CoV-2 was not detected in the sperm samples of cancer patients who were PCR+, the infection appears to impact sperm parameters, likely due to inflammation.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发的新型冠状病毒肺炎疫情，促使有关部门建议暂停辅助生殖技术项目，转而关注癌症患者的生育力保存。SARS-CoV-2是否存在于精液中仍存在争议。这项多中心前瞻性队列研究在12所大学医学中心开展，旨在通过逆转录聚合酶链反应（RT-PCR）确定癌症患者的精子/精浆中是否存在SARS-CoV-2，并评估其对标准精液参数的影响。通过酶联免疫吸附测定（ELISA）检测精液中细胞因子和肿瘤坏死因子-α（TNF-α）的水平。我们招募了129名在2020年7月7日至2021年6月30日期间进行精子冷冻保存的男性。其中63人被纳入研究，并通过RT-PCR和/或血清学方法对其鼻拭子样本进行新型冠状病毒肺炎检测。所有患者在精液采集当天均无症状：50人未感染，8人鼻拭子检测呈阳性（PCR阳性），5人血清学检测呈阳性。在精液或精子中未检测到SARS-CoV-2核糖核酸（RNA）。与未感染组相比，PCR阳性组的射精量显著降低（中位数[四分位间距]：2.6毫升[1.6 - 3.4] 对 4.6毫升[2.6 - 5.2]，p < 0.05）。与血清学检测呈阳性组相比，PCR阳性组的精子总活力和前向运动率较低（分别为32.5%[25.0 - 45.0] 对 50%[49.0 - 55.0]，p < 0.05；以及22.5%[10.0; 32.5] 对 44.5%[40 - 49]，p < 0.05）。与未感染组（0皮克/毫升[0 - 0.4]）相比，PCR阳性组观察到更高的TNF-α水平（1.9皮克/毫升[0 - 3.9]），p < 0.05。尽管在PCR阳性的癌症患者精子样本中未检测到SARS-CoV-2，但该感染似乎会影响精子参数，可能是由于炎症所致。
